SPLV — the Invesco S&P 500 Low Volatility ETF — enters the final days of August with its options market flashing the most defensive signal in months, even as short sellers quietly pare positions.
The options picture has shifted dramatically since last week's note. The put/call ratio jumped to 3.44 on August 25, more than double the 1.76 reading flagged just six days ago. Against the 20-day average of 1.69, that puts the PCR nearly 2.8 standard deviations above the mean — an unusually elevated reading for a fund whose investor base typically seeks calm rather than directional bets. The 52-week high on the PCR is 5.44, so this isn't at the absolute ceiling, but it is well into territory that signals concentrated demand for downside protection. Investors are, in effect, buying insurance on their insurance.
The short-selling story has moved in the opposite direction, and that contrast is worth naming. Short interest dropped 17.7% in a single session on August 25, pulling back to 2.59% of float — down from a recent peak near 3.2% mid-month and now at the lower end of its two-month range. Borrow availability has loosened sharply too, jumping to 106% from just 39% the prior session, the most room in the lending pool since early August. Cost to borrow has eased to 3.07% from the 3.56% seen on August 24, remaining within the 2.4%–3.6% band it has occupied all summer. The ORTEX short score has also drifted lower, from a recent high of 53.0 to 50.3 — close to neutral. Short sellers are backing away, not pressing.
The divergence between options and short positioning captures the tension in SPLV right now. Put buyers are hedging aggressively into late August while short sellers are covering. One plausible read: holders of SPLV are using the options market to protect against a broader equity drawdown rather than targeting the ETF itself. The fund is down 2% on the month to $75.64, giving up some of the defensive premium it typically holds during risk-off episodes.
The dividend cadence adds a small mechanical note. SPLV distributed $0.1418 per share in late August, consistent with the $0.13–$0.14 range paid through 2026. The yield remains modest in absolute terms but matters to the income-oriented holders the fund attracts.
What to watch: whether the elevated PCR reflects genuine fear of a near-term equity decline or simply mechanical hedging around the dividend date — and whether put demand retreats as cleanly as it appeared, or persists into September.
See the live data behind this article on ORTEX.
Open SPLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
